- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03032731
Trial of a New Online Programme for Physical Activity and Healthy Eating.
Trial of a Self-directed Behaviour Change Intervention for Physical Activity and Healthy Eating.
Many healthy lifestyle interventions have been developed to help people change their activity and diet, lose weight and thus reduce their risk of developing type 2 diabetes (T2DM) and cardiovascular disorders (CVD). However, these interventions often fail to engage their target audience, which undermines their effectiveness in changing behaviour and health outcomes.
The purpose of this study is to investigate the effectiveness of a self-directed, website-based intervention to promote physical activity and healthy dietary behaviours. The intervention frames health information from a novel perspective, which our previous work has indicated can help to promote interest in the health information and improve attitudes, self-efficacy and motivation towards physical activity and healthy dietary behaviours.
The intervention comprises a website of information resources and personal recording areas to set goals and monitor activity and diet, weekly emails and pedometers. In this trial we aim to see whether the intervention has any impact on people's physical activity and diet, as well as their risk of developing CVD and T2DM. The intervention will be compared with a control condition in which participants will be shown standard resources available on NHS websites. Overweight/obese (BMI 25 - 39.5) males and females aged 35-74 years will be recruited from the community. The active intervention will last 6 weeks (during this period participants will receive weekly emails from the research team) and there will be a 6-week follow-up phase (in which participants will still have access to the website but contact from the research team). Activity, diet, disease risk markers and psychological antecedents of behaviour will be assessed at baseline, post-intervention (6-weeks) and post follow-up (12- weeks).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bath, United Kingdom, BA2 7AY
- University of Bath
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to give informed consent to participate in the study.
- Male or female and aged between 35-74 years.
- Defined as overweight or obese, i.e. BMI>25kg/m2.
- Able to travel to the university for assessment days.
Exclusion Criteria:
- Individuals who are not fluent in the English language, and who do not have access to and do not regularly use the internet and an email account.
- Individuals diagnosed with coronary heart disease, chronic kidney disease, type 2 diabetes, stroke, heart failure, severe hypertension (BP>180/110mmHg) and peripheral arterial disease.
- BMI>40kg/m2 (morbidly obese).
- Currently using weight loss drugs or other medication that can affect weight.
- Any reported recent (i.e. last 6 months) shift (>5%) in body mass or large change in habitual lifestyle.
- Individuals unable to change their physical activity (e.g. through disability).
- Current (pre-baseline) or recent (i.e. last 2 months) participation in another research trial or lifestyle supportive intervention or referral.
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Website and pedometer Intervention
Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals.
The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website.
For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress.
After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
|
Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
|
Other: Control
Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)).
Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks.
Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
|
Standard, publicly available NHS resources for healthy lifestyles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean daily physical activity level (PAL)
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Mean daily physical activity level (PAL) will be assessed using accelerometers (BodyMedia, worn on the upper arm), worn for a continuous 7-day period, being removed during this time only for water-based activities such as showering or swimming.
The accelerometers gather minute by minute total energy expenditure (TEE) data, which will be used to calculate PAL (PAL = TEE/BMR, where BMR = basal metabolic rate, to be calculated using the Schofield equation).
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Change in mean daily energy intake (EI)
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Mean daily energy intake (EI) will be assessed using 3-day weighed food diaries, incorporating 2 week days and 1 weekend day .
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting plasma glucose concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of glucose concentration in the blood plasma at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Fasting plasma insulin concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of insulin concentration in the blood plasma at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Fasting triglyceride concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of triglyceride concentration in the blood serum at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Fasting total cholesterol concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of total concentration in the blood serum at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Fasting LDL cholesterol concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of LDL concentration in the blood serum at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Fasting HDL cholesterol concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of HDL concentration in the blood serum at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
C-reactive protein (CRP) concentration
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of CRP concentration in the blood serum at rest across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Body mass index (BMI)
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of BMI (defined as mass in kg divided by height in metres squared) across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Waist circumference
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of waist circumference (in centimetres) across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Blood pressure
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Comparison of blood pressure (systolic/diastolic mmHG) across all three measurement points.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Quality of diet
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Diet quality will be assessed based on the proportion of fibre, free sugars and refined carbohydrates, and saturated fats in the diet.
The intervention aims to promote an increase in fibre intake and decrease in free sugar, refined carbohydrate and saturated fat intake.
Data will be collected using 3-day weighed food diaries, incorporating 2 week days and 1 weekend day.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Motivation for physical activity
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Motivation will be assessed using the Behavioural Regulation for Exercise Questionnaire 3 (BREQ 3: Markland & Tobin, 2004; Wilson, Rodgers, Loitz & Scime, 2006) adapted for physical activity.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Motivation for healthy eating
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Motivation will be assessed using the Behavioural Regulation for Exercise Questionnaire 3 (BREQ 3: Markland & Tobin, 2004; Wilson, Rodgers, Loitz & Scime, 2006) adapted for diet.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Self-efficacy for physical activity and healthy eating
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Self-efficacy will be measured using the Barriers Self-Efficacy Scale for Exercise (BARSE; McAuley, 1992) adapted for physical activity.
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Self-efficacy for healthy eating
Time Frame: Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Self-efficacy will be measured using the self-efficacy scale for eating a healthy diet developed by Pawlak and Colby (2009).
|
Baseline, 6 weeks and 12 weeks after starting the intervention/control period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dylan Thompson, PhD, University of Bath
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EP 16/17 034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight/Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
National Taiwan University HospitalCompleted
Clinical Trials on Website and pedometer intervention
-
VA Boston Healthcare SystemUniversity of Michigan; VA Ann Arbor Healthcare SystemCompletedCOPD | Internet AccessUnited States
-
VA Office of Research and DevelopmentCompletedEmphysema | COPD | Chronic BronchitisUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/S; Copenhagen University Hospital at Herlev; Danish Cancer Society and other collaboratorsCompleted
-
Mansoura UniversityRecruitingFatigue | Physical InactivityEgypt
-
Arizona State UniversityKarolinska InstitutetCompleted
-
Northwestern UniversityCompletedEnd Stage Kidney DiseaseUnited States
-
University of AlbertaAlberta Health services; Athabasca UniversityTerminatedImpaired Glucose Tolerance | PrediabetesCanada
-
University of ValenciaCompleted
-
University of Southern DenmarkCompletedPhysical InactivityDenmark
-
The Policy & Research GroupDepartment of Health and Human ServicesRecruiting